Literature DB >> 21733839

The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site.

Hugh P Morgan1, Iain W McNae, Matthew W Nowicki, Wenhe Zhong, Paul A M Michels, Douglas S Auld, Linda A Fothergill-Gilmore, Malcolm D Walkinshaw.   

Abstract

Ehrlich's pioneering chemotherapeutic experiments published in 1904 (Ehrlich, P., and Shiga, K. (1904) Berlin Klin. Wochenschrift 20, 329-362) described the efficacy of a series of dye molecules including trypan blue and trypan red to eliminate trypanosome infections in mice. The molecular structures of the dyes provided a starting point for the synthesis of suramin, which was developed and used as a trypanocidal drug in 1916 and is still in clinical use. Despite the biological importance of these dye-like molecules, the mode of action on trypanosomes has remained elusive. Here we present crystal structures of suramin and three related dyes in complex with pyruvate kinases from Leishmania mexicana or from Trypanosoma cruzi. The phenyl sulfonate groups of all four molecules (suramin, Ponceau S, acid blue 80, and benzothiazole-2,5-disulfonic acid) bind in the position of ADP/ATP at the active sites of the pyruvate kinases (PYKs). The binding positions in the two different trypanosomatid PYKs are nearly identical. We show that suramin competitively inhibits PYKs from humans (muscle, tumor, and liver isoenzymes, K(i) = 1.1-17 μM), T. cruzi (K(i) = 108 μM), and L. mexicana (K(i) = 116 μM), all of which have similar active sites. Synergistic effects were observed when examining suramin inhibition in the presence of an allosteric effector molecule, whereby IC(50) values decreased up to 2-fold for both trypanosomatid and human PYKs. These kinetic and structural analyses provide insight into the promiscuous inhibition observed for suramin and into the mode of action of the dye-like molecules used in Ehrlich's original experiments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733839      PMCID: PMC3173065          DOI: 10.1074/jbc.M110.212613

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei.

Authors:  Arun Pal; Belinda S Hall; Mark C Field
Journal:  Mol Biochem Parasitol       Date:  2002-07       Impact factor: 1.759

2.  Suramin enters and accumulates in low pH intracellular compartments of v-sis-transformed NIH 3T3 cells.

Authors:  S S Huang; H A Koh; J S Huang
Journal:  FEBS Lett       Date:  1997-10-27       Impact factor: 4.124

Review 3.  Recent research on the biological activity of suramin.

Authors:  T E Voogd; E L Vansterkenburg; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1993-06       Impact factor: 25.468

4.  Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding site.

Authors:  M Klinger; M Freissmuth; P Nickel; M Stäbler-Schwarzbart; M Kassack; J Suko; M Hohenegger
Journal:  Mol Pharmacol       Date:  1999-03       Impact factor: 4.436

5.  Effect of suramin on the human pathogen Candida albicans: implications on the fungal development and virulence.

Authors:  Lys Adriana Braga-Silva; André Luis Souza dos Santos; Maristela Barbosa Portela; Thaïs Souto-Padrón; Rosangela Maria de Araújo Soares
Journal:  FEMS Immunol Med Microbiol       Date:  2007-08-29

6.  Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Authors:  Matthew B Boxer; Jian-kang Jiang; Matthew G Vander Heiden; Min Shen; Amanda P Skoumbourdis; Noel Southall; Henrike Veith; William Leister; Christopher P Austin; Hee Won Park; James Inglese; Lewis C Cantley; Douglas S Auld; Craig J Thomas
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

7.  The phosphoglycerate kinases from Trypanosoma brucei. A comparison of the glycosomal and the cytosolic isoenzymes and their sensitivity towards suramin.

Authors:  O Misset; F R Opperdoes
Journal:  Eur J Biochem       Date:  1987-02-02

Review 8.  Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.

Authors:  E Eigenbrodt; M Reinacher; U Scheefers-Borchel; H Scheefers; R Friis
Journal:  Crit Rev Oncog       Date:  1992

Review 9.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  29 in total

1.  Conformational Dynamics and Allostery in Pyruvate Kinase.

Authors:  Katherine A Donovan; Shaolong Zhu; Peter Liuni; Fen Peng; Sarah A Kessans; Derek J Wilson; Renwick C J Dobson
Journal:  J Biol Chem       Date:  2016-02-15       Impact factor: 5.157

2.  Small-molecule modulators of methyl-lysine binding for the CBX7 chromodomain.

Authors:  Chunyan Ren; Keita Morohashi; Alexander N Plotnikov; Jean Jakoncic; Steven G Smith; Jiaojie Li; Lei Zeng; Yoel Rodriguez; Vivian Stojanoff; Martin Walsh; Ming-Ming Zhou
Journal:  Chem Biol       Date:  2015-02-05

3.  Reconstitution of Staphylococcus aureus Lipoteichoic Acid Synthase Activity Identifies Congo Red as a Selective Inhibitor.

Authors:  Christopher R Vickery; B McKay Wood; Heidi G Morris; Richard Losick; Suzanne Walker
Journal:  J Am Chem Soc       Date:  2018-01-09       Impact factor: 15.419

Review 4.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

Review 5.  An overview of structure, function, and regulation of pyruvate kinases.

Authors:  Norbert Schormann; Katherine L Hayden; Paul Lee; Surajit Banerjee; Debasish Chattopadhyay
Journal:  Protein Sci       Date:  2019-08-12       Impact factor: 6.725

Review 6.  100 Years of Suramin.

Authors:  Natalie Wiedemar; Dennis A Hauser; Pascal Mäser
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

7.  Stoking the drug target pipeline for human African trypanosomiasis.

Authors:  Margaret A Phillips
Journal:  Mol Microbiol       Date:  2012-08-28       Impact factor: 3.501

8.  Crystal structure of Cryptosporidium parvum pyruvate kinase.

Authors:  William J Cook; Olga Senkovich; Khadijah Aleem; Debasish Chattopadhyay
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

9.  A new family of covalent inhibitors block nucleotide binding to the active site of pyruvate kinase.

Authors:  Hugh P Morgan; Martin J Walsh; Elizabeth A Blackburn; Martin A Wear; Matthew B Boxer; Min Shen; Henrike Veith; Iain W McNae; Matthew W Nowicki; Paul A M Michels; Douglas S Auld; Linda A Fothergill-Gilmore; Malcolm D Walkinshaw
Journal:  Biochem J       Date:  2012-11-15       Impact factor: 3.857

Review 10.  Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents.

Authors:  Bhagyashri Rathod; Shivam Chak; Sagarkumar Patel; Amit Shard
Journal:  RSC Med Chem       Date:  2021-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.